This guide is currently available in English. A Spanish version is in progress.
Sourcing Exosomes in Missouri
Licensed Missouri practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. Missouri buyers need their own professional license and NPI; the out-of-state drug distributor license is the supplier’s obligation, not the purchaser’s.
Missouri put its stem cell provision in the constitution rather than a statute. Amendment 2 of 2006 guarantees that research and treatment permitted under federal law may be conducted and provided in the state, which means it adds no state authorization of its own. What a Missouri practice actually plans around is the collaborative practice arrangement, one of the most supervision-heavy NP frameworks in the country.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Missouri? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | None |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | Yes |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material; compounded preparations available through the 503A pharmacy partner |
| Last reviewed | 16 October 2026 |
Ordering from Missouri
ExaVeyra ships to licensed practices in all 50 states, Missouri included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active Missouri professional license in good standing, verifiable through the Division of Professional Registration’s online licensee search at pr.mo.gov.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- A Missouri resale exemption certificate (Form 149) if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
Missouri licenses drug distributors through the Board of Pharmacy within the Division of Professional Registration. The rule is written at the shipping event: an out-of-state wholesale drug distributor shall not ship, mail, or deliver prescription drugs into Missouri without first obtaining a license, and RSMo 338.337 makes it unlawful for an out-of-state wholesale distributor, pharmacy distributor, drug outsourcer, or third-party logistics provider to do business in the state unlicensed. The statutory definition covers legend drugs and drug-related devices, and an out-of-state distributor may qualify by reciprocity on its home-state license. The license sits with the distributor, not with the purchasing practice.
Mo. Rev. Stat. 338.330 to 338.340; 20 CSR 2220-5.020 · Missouri Board of Pharmacy, Division of Professional Registration
Missouri regenerative-medicine law
Missouri has not enacted a statute specific to stem cell or regenerative therapies. Practice in this area is governed by the state's general medical practice and professional licensing rules, alongside federal law.
Missouri has no statute authorizing, conditioning, or requiring disclosure for unapproved regenerative therapy in a clinical setting, so federal law is the only layer that addresses it. What Missouri does have is Article III, Section 38(d) of its constitution, adopted as Amendment 2 in November 2006 and effective 7 December 2006. It guarantees that stem cell research permitted under federal law may be conducted in Missouri and that federally permitted stem cell treatment may be provided to patients here, bans human cloning, limits how blastocysts may be sourced, and bars their sale. Because it reaches only what federal law already permits, it adds no state authorization of its own, and clinical practice remains governed by chapter 334, the boards, and federal law.
How this applies to exosomes
Missouri’s constitutional provision is written around stem cell research and stem cell treatment permitted under federal law, and exosomes are acellular extracellular vesicles rather than stem cells, so Article III, Section 38(d) does not reach them either to permit or to restrict. Nor does its deference to federal law change anything for an exosome product: federal law governs regardless, and under it no exosome product has been approved by the FDA for administration to humans. Missouri has enacted no statute on regenerative products of any kind. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a Missouri practice
Missouri is an arrangement state, which is the practical thing to plan around. The collaborative practice arrangement is a signed document with specific proximity, presence, and chart-review mechanics, and the Board of Registration for the Healing Arts and the Board of Nursing both police its terms. A practice built on NP or PA delivery budgets for genuine recurring physician time rather than a signature.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed by the Missouri Board of Registration for the Healing Arts may perform medical acts within their scope and are the source of every collaborative practice arrangement, which chapter 334 uses in place of free-form delegation for NPs and PAs. |
| NP / APRN | Nurse practitioners practice under a written collaborative practice arrangement with a physician under RSMo 334.104, with no route to independent practice. The arrangement carries geographic proximity set by board rule, an initial period with the collaborating physician continuously present, review of at least ten percent of charts every fourteen days (twenty percent where controlled substances are prescribed), and physician presence at least once every two weeks. Geographic proximity may be waived where the arrangement outlines the use of telehealth. |
| PA | Physician assistants practice under a written collaborative practice arrangement under RSMo 334.735 and may not practice where the collaborating physician is not immediately available for consultation. The arrangement lists practice locations, requires a displayed disclosure that patients may be seen by a PA, and carries ten percent chart review every fourteen days. |
| RN | Registered nurses may perform delegated treatments within their license and under an order from a provider with authority to issue one, after that provider has evaluated the patient. An RN does not diagnose, prescribe, or independently select a treatment. |
Good faith examination
Missouri expects a patient evaluation by a provider with authority to conduct it, and an order, before a delegated treatment is administered. Because nurse practitioners practice under collaborative arrangements rather than independently, the evaluating provider operates within that arrangement’s terms. Confirm current expectations with the Board of Registration for the Healing Arts and the Board of Nursing.
Ownership and clinic licensing
Missouri does not codify a corporate practice of medicine prohibition, and published summaries generally describe the state as not enforcing the doctrine, so entity ownership is more open here than in Texas, New York, or Michigan. The flexibility runs to ownership, not to practice: cosmetic injections and similar services remain the practice of medicine, performed by or delegated from licensed providers, and a practice offering them still plans around a physician in the collaborative structure. Confirm the structure with Missouri counsel before opening.
Cold chain into Missouri
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Missouri order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| St. Louis | St. Louis City | Largest eastern Missouri market, anchored by academic medicine. |
| Kansas City | Jackson | Largest western Missouri market, shared with the Kansas side of the metro. |
| Chesterfield | St. Louis | Dense west-county med spa and dermatology corridor. |
| Springfield | Greene | Southwest Missouri hub serving the Ozarks region. |
| Columbia | Boone | Mid-Missouri market with a university medical presence. |
- Missouri orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Every shipment arrives with the manufacturer’s handling instructions and the Certificate of Analysis for its lot.
Wholesale exosome supply by city in Missouri
Each city page covers local receiving conditions, delivery disruptions and business license rules for Missouri practices in that area.
Practice types we supply in Missouri
Missouri licensing and verification
Missouri Board of Registration for the Healing Arts
Sets geographic proximity and collaborative practice rules with the Board of Nursing.
Missouri State Board of Nursing
Missouri Board of Pharmacy
Issues in-state and out-of-state drug distributor licenses.
Missouri Department of Revenue
Sales tax registration and resale exemption certificates.
Missouri sourcing questions
- Does Missouri have a stem cell law?
- Missouri’s provision is constitutional rather than statutory. Article III, Section 38(d), adopted as Amendment 2 in 2006, guarantees that stem cell research and treatment permitted under federal law may be conducted and provided in Missouri, bans human cloning, and bars the sale of blastocysts. Because it reaches only what federal law already permits, it adds no state authorization, and exosome products remain governed by federal law, under which no exosome product is FDA-approved for administration to humans.
- Can a nurse practitioner run a practice in Missouri without a physician?
- No. Missouri nurse practitioners practice under a written collaborative practice arrangement with a physician under RSMo 334.104, with no route to independent practice. The arrangement carries geographic proximity, an initial period with the physician continuously present, chart review of ten to twenty percent every fourteen days, and physician presence at least once every two weeks, so a practice built on NP delivery budgets for genuine recurring physician time.
- Does Missouri enforce the corporate practice of medicine?
- Missouri does not codify the prohibition, and published summaries generally describe the state as not enforcing the doctrine, which makes entity ownership more open here than in Texas or New York. The flexibility does not extend to clinical work: injections and similar services remain the practice of medicine and run through licensed providers and collaborative arrangements. Treat the structure as a question for Missouri counsel.
- Does my Missouri clinic need a drug distributor license to buy exosomes?
- No. The out-of-state wholesale drug distributor license under RSMo 338.330 to 338.340 and 20 CSR 2220-5.020 is held by the distributor shipping into Missouri, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- Are exosomes FDA approved?
- No exosome product has been approved by the FDA for administration to humans, and the FDA said so directly in its 2019 public safety notification on exosome products. ExaVeyra supplies Kimera exosome material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot traceability on every vial.
- How long does cold-chain shipping take to Missouri?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- RSMo 338.330, drug distributor definitions (accessed 16 October 2026)
- RSMo 338.337, out-of-state drug distributor licensing (accessed 16 October 2026)
- Missouri Constitution, Article III, Section 38(d) (Amendment 2 of 2006) (accessed 16 October 2026)
- RSMo 334.104, collaborative practice arrangements (accessed 16 October 2026)
- RSMo 334.735, physician assistant collaborative practice (accessed 16 October 2026)
- Missouri Board of Pharmacy, Division of Professional Registration (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Clinical guidelinesupports: Defines the field’s current characterization and reporting standard for extracellular vesicles, the benchmark behind the COA and lot documentation this page describes.
- Witwer KW, Van Balkom BWM, Bruno S, et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. Journal of Extracellular Vesicles, 2019. doi:10.1080/20013078.2019.1609206 PMID:31069028Consensus statementsupports: ISEV and ISCT position on what must be documented for an MSC-derived EV preparation, which is the documentation standard a buying practice should hold a supplier to.
- Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. Journal of Extracellular Vesicles, 2015. doi:10.3402/jev.v4.30087 PMID:26725829Consensus statementsupports: ISEV position on manufacturing and safety documentation for EV-based products in trials, supporting this page’s framing that clinical use runs through regulated research.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.